医学
内科学
危险系数
卵巢癌
胃肠病学
叶酸受体
人口
无进展生存期
随机对照试验
阿霉素
化疗
癌症
泌尿科
肿瘤科
置信区间
癌细胞
环境卫生
作者
R. Wendel Naumann,Robert L. Coleman,Robert A. Burger,Edward A. Sausville,E. Kutarska,Sharad Ghamande,Nashat Gabrail,Stephen DePasquale,Elżbieta Nowara,Lucy Gilbert,Robert H. Gersh,Michael Teneriello,Wael A. Harb,Panagiotis A. Konstantinopoulos,Richard T. Penson,James T. Symanowski,C. Lovejoy,Christopher P. Leamon,David Morgenstern,Richard A. Messmann
标识
DOI：10.1200/jco.2013.49.7685
摘要
Vintafolide plus PLD is the first combination to demonstrate an improvement over standard therapy in a randomized trial of patients with platinum-resistant ovarian cancer. Etarfolatide can identify patients likely to benefit from vintafolide.
科研通智能强力驱动
Strongly Powered by AbleSci AI
PDF的下载单位、IP信息已删除
(2025-6-4)
AllRightReserved
归尘
仰望喀纳斯的星空
GingerF
HFH
1111
帅气碧萱
YifanWang
无极微光
Ethan
Criminology34
OK
贪玩的秋柔
Hayat
嘻嘻哈哈
mmyhn
fearless
yy
Yas
核桃
皖公网安备34019202002308
